CPE
Daniel A. Hussar, PhD
Part 1 (Pharmacy Today, May 2022) of this series on new FDA-approved therapeutic agents marketed in 2021 reviewed 4 new therapeutic agents: atogepant (Qulipta—AbbVie), viloxazine hydrochloride (Qelbree—Supernus), serdexmethylphenidate chloride/dexmethylphenidate hydrochloride (Azstarys—Corium), and aducanumab-avwa (Aduhelm—Biogen). This second and concluding part of this series reviews 5 additional agents which FDA fully approved or provided an EUA and which became available in 2021: nirmatrelvir/ritonavir (Paxlovid—Pfizer), molnupiravir (Lagevrio—Merck), vibegron (Gemtesa—Urovant), tirbanibulin (Klisyri—Almirall), and clascoterone (Winlevi—Sun Dermatology).
Following the review of each new therapeutic agent, the new drug is compared with the older medication(s) with which it is most similar in properties and uses, and its advantages and disadvantages are identified. (Advantages and disadvantages are identified as they were at the time the new drug was first marketed and do not reflect approval of additional new drugs and/or changes that occurred after the drug was initially marketed.)
CPE assessment
This assessment must be taken online; please see “CPE information” below for further instructions. The online system will present these questions in random order to help reinforce the learning opportunity. There is only one correct answer to each question.
CPE information
To obtain 1 hour of CPE credit for this activity, complete the CPE exam and submit it online at www.pharmacist.com/education. A Statement of Credit will be awarded for a passing grade of 70% or better. You have two opportunities to successfully complete the CPE exam. Pharmacists and technicians who successfully complete this activity before October 1, 2027, can receive credit. Your Statement of Credit will be available online immediately upon successful completion of the CPE exam.
This policy is intended to maintain the integrity of the CPE activity. Learners who successfully complete this activity by the expiration date can receive CPE credit. Please visit CPE Monitor for your statement of credit/transcript.
To claim credit
1. Go to http://apha.us/CPE.
2. Log in to your APhA account, or register as a new user.
3. Select “Enroll Now” or “Add to Cart” (click “View Cart” and “Check Out”).
4. Complete the assessment and evaluation.
5. Click “Claim Credit.” You will need to provide your NABP e-profile ID number to obtain and print your statement of credit.
Assistance is available Monday through Friday from 8:30 am to 5:00 pm ET at APhA InfoCenter by calling 800-237-APhA (2742)
or by e-mailing infocenter@aphanet.org.